Navigation Links
Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death
Date:5/6/2011

NATICK, Mass., May 6, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch and first implants of its ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) in Europe and other international markets. They are the world's smallest and thinnest high-energy devices to treat heart failure and sudden cardiac death and offer excellent longevity.

"These devices build on the technological advancements of COGNIS® and TELIGEN® by providing options to customize therapy for individual patients," said Professor Joachim Winter, M.D., who performed one of the first implants of the ENERGEN ICD with Dong-In Shin, M.D., at the University Hospital Dusseldorf in Germany.  "The small profile, coupled with the 4-SITE™ connector system, allowed for an easy implant with a less pronounced physical appearance for the patient."

"Physicians and patients will truly appreciate the longevity of these devices since it may reduce the need for additional implant surgeries," said Peter Lecher, M.D., who performed one of the first implants of the ENERGEN CRT-D with Gunther Prenner, M.D., at the Medical University in Graz, Austria.  "Additionally, the new therapy options, combined with the LATITUDE® Patient Management system, increase the variety of diagnostic parameters to help treat heart failure patients."

Most of the new ENERGEN and PUNCTUA devices offer the 4-SITE™ DF4 connector system option, designed to simplify the implant procedure and comply with international connector standards.  Additionally, nearly all models are compatible with Boston Scientific's LATITUDE® Patient Management system, which enables physicians to remotely monitor implantable cardiac device patients between on-site office visits.

"The
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... and their partners have found that their proprietary microbicide ... of multiple sexually transmitted infections (STIs) in both the ... 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study ... effective against multiple strains of HIV, and has a ... viruses of at least eight hours prior to exposure. ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... 02 April 2011: Exciting new data presented today at ... in chronic hepatitis C (HCV) patients suppressed the emergence ... of sustained virological response - undetectable HCV RNA - ... therapy study, HCV patients were given four drugs in ...
... compounds that inhibit two of the most frequently mutated ... I trial, according to data presented at the AACR ... The research, presented by Johanna Bendell, M.D., tests ... which inhibits PI3K. Bendell, director of Gastrointestinal Oncology ...
... , FRIDAY, April 1 (HealthDay News) -- Updated ... go to camp were released this week by the American ... should consider their child,s interests, skills and overall well-being, to ... Parents also need to medically and mentally prepare their ...
... of Pennsylvania School of Medicine have determined that a ... association with one of the biological processes associated with ... in the latest issue of Nature Communications. ... proteins associated with a suite of neurodegenerative diseases. Tau ...
... , FRIDAY, April 1 (HealthDay News) -- Ballet ... put tremendous strain on certain parts of the body, so ... the American Academy of Orthopaedic Surgeons. "When it comes ... but the fact of the matter is that ballet is ...
... -- An award-winning Loyola University Health System study ... of smoke-inhalation patients., Contrary to expectations, patients who ... in their lungs than patients who survived., "Perhaps ... dysfunction will allow for therapies that further improve ...
Cached Medicine News:Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:Combining MEK and PI3K inhibitors appears encouraging in a safety study with early signs of anti-tumor activity 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2Health News:Penn study suggests another avenue for detecting Alzheimer's disease 2Health News:Rigors of Ballet Require Careful Training 2Health News:Surprising finding from smoke inhalation study 2
Tennant straight tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
McPherson straight tying forceps have straight shafts, tying platforms 4 mm, serrated handle, polished finish, overall length 85 mm....
Jayle tying forceps, straight....
Medicine Products: